Related Experiment Video
Updated: Jan 27, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
The Current Status of Radionuclide Tumor Targeting Diagnosis and Therapy Based on FAP-2286: From Preclinical Studies
Huajun Liu1,2,3,4, Zhen Yang5, Junzheng Wang1,2,3,4
1Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Abstract:
In recent years, fibroblast activation protein (FAP) has demonstrated significant potential in oncology, and the development of FAP-targeted therapeutic agents has increasingly become a key research focus in the fields of molecular imaging and radionuclide therapy. Among these, FAP inhibitor (FAPI)-based small molecules have demonstrated favorable pharmacokinetics and imaging potential, showing promising potential in the diagnosis and treatment of tumors. As a peptide-based radiopharmaceutical derived from structural optimization of FAPI, FAP-2286 consists of a FAP-specific binding peptide conjugated to a DOTA chelator. It not only preserves the high affinity and favorable imaging characteristics of small-molecule FAPI tracers but also markedly prolongs tumor retention, thereby enabling both diagnostic and therapeutic applications. Preclinical and early clinical studies have shown encouraging results, characterized by prolonged in vivo retention and a favorable safety profile, supporting its use as a theranostic agent. This review provides a comprehensive overview of the current literature on FAP-2286, from preclinical development to clinical translation, highlighting its diagnostic value, the status of FAP-targeted radionuclide therapy, and the challenges and opportunities in advancing FAP-based theranostics.
Insights
FAP-2286, a novel peptide-based radiopharmaceutical targeting fibroblast activation protein (FAP), shows promise for cancer diagnosis and therapy. Its prolonged tumor retention and safety profile support its role as a theranostic agent.
Area of Science:
- Oncology
- Molecular Imaging
- Radiopharmaceutical Therapy
Background:
- Fibroblast activation protein (FAP) is a key target in oncology.
- FAP inhibitor (FAPI)-based small molecules show potential for tumor diagnosis and treatment.
- Developing targeted therapeutic agents for FAP is a major research focus.
Purpose of the Study:
- To review the development and potential of FAP-2286 as a theranostic agent.
- To highlight the diagnostic value and therapeutic applications of FAP-2286.
- To discuss the current status of FAP-targeted radionuclide therapy.
Main Methods:
- FAP-2286 is a peptide-based radiopharmaceutical derived from FAPI.
- It combines a FAP-specific binding peptide with a DOTA chelator.
- Structural optimization enhances tumor retention compared to small-molecule FAPI tracers.
Main Results:
- FAP-2286 preserves high affinity and favorable imaging characteristics.
- It demonstrates markedly prolonged tumor retention.
- Preclinical and early clinical studies show encouraging results, including a favorable safety profile.
Conclusions:
- FAP-2286 exhibits potential as a theranostic agent for FAP-expressing tumors.
- Its prolonged in vivo retention supports both diagnostic and therapeutic applications.
- Further research is needed to advance FAP-based theranostics.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Applications of Epidermal Stem Cells
Local Anesthetics: Clinical Application as Spinal Anesthesia
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Aneurysm II: Clinical Manifestations and Diagnostic Studies

